Comparative Pharmacology
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus SYNCURINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus SYNCURINE.
PANCURONIUM BROMIDE vs SYNCURINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing skeletal muscle paralysis.
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
0.1-0.2 mg/kg IV bolus for paralysis, repeat 0.05-0.1 mg/kg as needed; maintenance infusion 0.5-1.5 mcg/kg/min IV.
None Documented
None Documented
Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure.
Terminal half-life: 2-5 hours (prolonged with renal impairment; up to 10 hours in severe impairment)
Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism.
Primarily renal excretion (50-70% unchanged drug), with biliary/fecal elimination (10-20%)
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent